Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Pharming Group NV (PHAR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: PHAR (1-star) is a SELL. SELL since 3 days. Profits (7.79%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $30.33
1 Year Target Price $30.33
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.79% | Avg. Invested days 20 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 752.57M USD | Price to earnings Ratio - | 1Y Target Price 30.33 |
Price to earnings Ratio - | 1Y Target Price 30.33 | ||
Volume (30-day avg) 3 | Beta 0.54 | 52 Weeks Range 6.65 - 12.61 | Updated Date 06/29/2025 |
52 Weeks Range 6.65 - 12.61 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.21 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -4.4% | Operating Margin (TTM) 0.96% |
Management Effectiveness
Return on Assets (TTM) 1.99% | Return on Equity (TTM) -6.78% |
Valuation
Trailing PE - | Forward PE 169.49 | Enterprise Value 756307624 | Price to Sales(TTM) 2.35 |
Enterprise Value 756307624 | Price to Sales(TTM) 2.35 | ||
Enterprise Value to Revenue 2.36 | Enterprise Value to EBITDA 35.42 | Shares Outstanding 68393104 | Shares Floating 654928595 |
Shares Outstanding 68393104 | Shares Floating 654928595 | ||
Percent Insiders - | Percent Institutions 0.08 |
Analyst Ratings
Rating 2 | Target Price 30.33 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Pharming Group NV
Company Overview
History and Background
Pharming Group NV was founded in 1988 in Leiden, Netherlands. It focuses on developing innovative protein replacement therapies for rare genetic diseases and specialty products. A key milestone was the approval of Ruconestu00ae.
Core Business Areas
- Rare Disease Therapies: Pharming develops and commercializes therapies for rare diseases, focusing on protein replacement therapies.
- Research and Development: Pharming invests in R&D to expand its product pipeline and develop new therapies for unmet medical needs.
Leadership and Structure
Sijmen de Vries is the Chief Executive Officer. The company has a management board and a supervisory board overseeing its operations.
Top Products and Market Share
Key Offerings
- Ruconest (C1-esterase inhibitor [recombinant]): Ruconest is Pharming's key product, used for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE). It has a substantial market share within the HAE treatment market. Competitors include Takeda (Cinryze), CSL Behring (Berinert), and BioCryst Pharmaceuticals (Orladeyo).
Market Dynamics
Industry Overview
The biopharmaceutical industry, especially the rare disease therapeutics market, is experiencing significant growth due to increased awareness, orphan drug incentives, and technological advancements. There are high barriers to entry but also high reward potential for successfully developed drugs.
Positioning
Pharming is a specialty biopharmaceutical company focused on developing and commercializing innovative protein replacement therapies. They have established a strong position in the HAE market with Ruconest.
Total Addressable Market (TAM)
The global hereditary angioedema (HAE) market is expected to reach several billion dollars. Pharming is positioned to capture a significant portion of this TAM with Ruconest and future pipeline products.
Upturn SWOT Analysis
Strengths
- Established product (Ruconest)
- Focus on rare diseases with unmet needs
- Strong R&D capabilities
- Experienced management team
Weaknesses
- Reliance on a single key product
- High R&D costs
- Competition from larger pharmaceutical companies
- Dependence on regulatory approvals
Opportunities
- Expansion of Ruconest indications
- Development of new therapies for other rare diseases
- Strategic partnerships and collaborations
- Geographic expansion
Threats
- Competition from new entrants
- Patent expiration of Ruconest
- Regulatory changes
- Pricing pressures
Competitors and Market Share
Key Competitors
- TAK
- CSL
- BCRX
Competitive Landscape
Pharming's advantage lies in Ruconest's specific mechanism and established safety profile. Disadvantages include its smaller size compared to larger competitors like Takeda and CSL Behring.
Major Acquisitions
LEO Pharma's Tru79fbu690dation Medicine Assets
- Year: 2023
- Acquisition Price (USD millions): 100
- Strategic Rationale: Expanded Pharming's pipeline with promising therapies for transplant rejection, diversifying beyond hereditary angioedema.
Growth Trajectory and Initiatives
Historical Growth: Pharming's historical growth has been driven by increasing sales of Ruconest. Please add additional quantitative historical figures for Revenue, Market Share etc.
Future Projections: Analysts project continued growth for Pharming based on increased adoption of Ruconest and potential new product launches. Please cite an average growth projection percentage
Recent Initiatives: Recent initiatives include expanding Ruconest's market reach, advancing pipeline programs, and exploring potential acquisitions.
Summary
Pharming Group NV is a specialty biopharmaceutical company with a focus on rare diseases, particularly hereditary angioedema. Ruconest drives its revenue, and it is expanding its pipeline through acquisitions. A risk is its reliance on one drug, the increasing competition in HAE, and the dependence on regulatory approvals. Further investments in R&D and strategic acquisitions would help it expand the product portfolio for growth and profitability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pharming Group NV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-12-23 | CEO & Executive Director Mr. Fabrice Chouraqui Ph.D., Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 404 | Website https://www.pharming.com |
Full time employees 404 | Website https://www.pharming.com | ||
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.